Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q62346457 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241221010730.0 | ||
| 008 | 241221nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q62346457 | ||
| 024 | ‡a 0000-0002-0187-8873 ‡2 orcid | ||
| 024 | ‡a 57189892319 ‡2 scopus | ||
| 035 | ‡a (OCoLC)Q62346457 | ||
| 100 | 0 | ‡a Benjamin N Schneider ‡c researcher ‡9 en | |
| 375 | ‡a 1 ‡2 iso5218 | ||
| 400 | 0 | ‡a Benjamin N Schneider ‡c wetenschapper ‡9 nl | |
| 670 | ‡a Author's AFMRD strategic plan: progress in governance | ||
| 670 | ‡a Author's Considerations for Medical Students and Advisors After an Unsuccessful Match | ||
| 670 | ‡a Author's Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance | ||
| 670 | ‡a Author's Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans | ||
| 670 | ‡a Author's Omentin-1 levels are reduced by pharmacologic doses of leptin, but remain unaffected by energy deprivation and display no day-night variation. | ||
| 909 | ‡a (orcid) 0000000201878873 ‡9 1 | ||
| 909 | ‡a (scopus) 57189892319 ‡9 1 | ||
| 919 | ‡a afmrdstrategicplanprogressingovernance ‡A AFMRD strategic plan: progress in governance ‡9 1 | ||
| 919 | ‡a considerationsformedicalstudentsandadvisorsafteranunsuccessfulmatch ‡A Considerations for Medical Students and Advisors After an Unsuccessful Match ‡9 1 | ||
| 919 | ‡a efficacyofmetreleptininobesepatientswithtype2diabetescellularandmolecularpathwaysunderlyingleptintolerance ‡A Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance ‡9 1 | ||
| 919 | ‡a leptinandamylinactinanadditivemannertoactivateoverlappingsignalingpathwaysinperipheraltissuesinvitroandexvivostudiesinhumans ‡A Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans ‡9 1 | ||
| 919 | ‡a omentin1levelsarereducedbypharmacologicdosesofleptinbutremainunaffectedbyenergydeprivationanddisplaynodaynightvariation ‡A Omentin-1 levels are reduced by pharmacologic doses of leptin, but remain unaffected by energy deprivation and display no day-night variation. ‡9 1 | ||
| 946 | ‡a b ‡9 1 | ||
| 996 | ‡2 NII|DA06303275 | ||
| 996 | ‡2 DNB|1277186359 | ||
| 996 | ‡2 BNF|17927766 | ||
| 996 | ‡2 CAOONL|ncf12098603 | ||
| 996 | ‡2 NUKAT|n 2009158873 | ||
| 996 | ‡2 LC|no2009181395 | ||
| 996 | ‡2 BNF|12877363 | ||
| 996 | ‡2 J9U|987007381544905171 | ||
| 996 | ‡2 NUKAT|n 2011144038 | ||
| 996 | ‡2 SIMACOB|407234563 | ||
| 996 | ‡2 DNB|170984621 | ||
| 996 | ‡2 DNB|1335512020 | ||
| 996 | ‡2 ISNI|0000000016824486 | ||
| 996 | ‡2 NTA|074063189 | ||
| 996 | ‡2 DNB|1155793005 | ||
| 996 | ‡2 LC|no2008178072 | ||
| 996 | ‡2 LC|n 85120155 | ||
| 996 | ‡2 NLA|000051754558 | ||
| 996 | ‡2 RERO|A012400838 | ||
| 996 | ‡2 ISNI|0000000081920597 | ||
| 996 | ‡2 NII|DA02926651 | ||
| 996 | ‡2 DNB|1332902863 | ||
| 996 | ‡2 LC|no2022113245 | ||
| 996 | ‡2 DNB|1019849312 | ||
| 996 | ‡2 KRNLK|KAC200603254 | ||
| 996 | ‡2 ISNI|000000008146005X | ||
| 996 | ‡2 BIBSYS|3051723 | ||
| 996 | ‡2 SUDOC|032682441 | ||
| 996 | ‡2 DNB|130293059 | ||
| 996 | ‡2 DNB|171781295 | ||
| 996 | ‡2 DNB|130464392 | ||
| 996 | ‡2 PLWABN|9810645235405606 | ||
| 996 | ‡2 NUKAT|n 2005091238 | ||
| 996 | ‡2 J9U|987007432014905171 | ||
| 996 | ‡2 LIH|LNB:C_f__j__l_;=CJ | ||
| 996 | ‡2 ISNI|0000000050979166 | ||
| 996 | ‡2 DNB|125403076X | ||
| 996 | ‡2 SUDOC|079414680 | ||
| 996 | ‡2 NTA|073057800 | ||
| 996 | ‡2 DNB|1068926430 | ||
| 996 | ‡2 LC|n 84104435 | ||
| 996 | ‡2 DNB|1158300956 | ||
| 996 | ‡2 LNB|LNC10-000224155 | ||
| 996 | ‡2 LC|no2019051319 | ||
| 996 | ‡2 DNB|105051940X | ||
| 996 | ‡2 LC|nb2021007126 | ||
| 996 | ‡2 DNB|1198353694 | ||
| 996 | ‡2 BNF|12366489 | ||
| 996 | ‡2 NKC|jo2017972498 | ||
| 996 | ‡2 NII|DA17200900 | ||
| 996 | ‡2 DNB|1053504179 | ||
| 996 | ‡2 DNB|1072470047 | ||
| 996 | ‡2 DNB|1254818707 | ||
| 996 | ‡2 DNB|1065067461 | ||
| 996 | ‡2 DNB|1043184007 | ||
| 996 | ‡2 LC|n 2009016692 | ||
| 996 | ‡2 DNB|1018128972 | ||
| 996 | ‡2 DNB|1210442221 | ||
| 996 | ‡2 LNL|6931 | ||
| 996 | ‡2 J9U|987007267767605171 | ||
| 996 | ‡2 SZ|135658764 | ||
| 996 | ‡2 LC|n 82055237 | ||
| 996 | ‡2 NTA|071106898 | ||
| 996 | ‡2 SUDOC|106976389 | ||
| 996 | ‡2 ISNI|0000000385979352 | ||
| 996 | ‡2 LIH|LNB:K_m_5;=BT | ||
| 996 | ‡2 DNB|1037568745 | ||
| 996 | ‡2 LC|n 2011183878 | ||
| 996 | ‡2 PLWABN|9812695091505606 | ||
| 996 | ‡2 RERO|A022265926 | ||
| 996 | ‡2 DNB|1100568999 | ||
| 996 | ‡2 SELIBR|288799 | ||
| 996 | ‡2 DNB|1280200464 | ||
| 996 | ‡2 J9U|987007273470605171 | ||
| 996 | ‡2 DNB|130133973 | ||
| 996 | ‡2 NII|DA0682798X | ||
| 996 | ‡2 LC|n 88605934 | ||
| 996 | ‡2 ISNI|0000000360076288 | ||
| 996 | ‡2 DNB|129924369X | ||
| 996 | ‡2 NTA|069150559 | ||
| 996 | ‡2 RERO|A003802833 | ||
| 996 | ‡2 RERO|A003802832 | ||
| 996 | ‡2 RERO|A003802830 | ||
| 996 | ‡2 NTA|107833174 | ||
| 996 | ‡2 DNB|1264956312 | ||
| 996 | ‡2 ISNI|0000000116984022 | ||
| 996 | ‡2 LC|n 91012808 | ||
| 996 | ‡2 ISNI|0000000058761727 | ||
| 996 | ‡2 DNB|1024949222 | ||
| 996 | ‡2 BLBNB|000339483 | ||
| 996 | ‡2 DNB|1030487553 | ||
| 996 | ‡2 CAOONL|ncf12136610 | ||
| 996 | ‡2 SUDOC|098259040 | ||
| 996 | ‡2 ISNI|000000002418217X | ||
| 996 | ‡2 NTA|364166584 | ||
| 996 | ‡2 BNC|981058509110606706 | ||
| 996 | ‡2 NKC|mzk2002148159 | ||
| 996 | ‡2 ISNI|000000002042934X | ||
| 996 | ‡2 DNB|1278712100 | ||
| 996 | ‡2 N6I|vtls001287125 | ||
| 996 | ‡2 J9U|987007380391405171 | ||
| 996 | ‡2 BIBSYS|90617357 | ||
| 996 | ‡2 LC|nr 94022494 | ||
| 996 | ‡2 BNF|12230998 | ||
| 996 | ‡2 SUDOC|148411207 | ||
| 996 | ‡2 DNB|135658764 | ||
| 996 | ‡2 SUDOC|26647960X | ||
| 996 | ‡2 ISNI|0000000051031131 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
